Therapeutic tools for dyslipidemia in peritoneal dialysis patients

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Patients on peritoneal dialysis (PD) have a high cardiovascular (C-V) risk.
• Dyslipidemia is a common complication in chronic kidney disease (CKD) and PD may worsen lipid profiles, promoting an atherogenic state.
• While lipid-lowering therapy reduces C-V mortality in the general population, its impact on PD patients is not well-defined.

Purpose of the Study:

• To review the current understanding of dyslipidemia in PD patients.
• To discuss therapeutic strategies for managing dyslipidemia in PD patients.
• To highlight the need for further research on reducing C-V mortality in this population.

Main Methods:

• Review of existing literature on dyslipidemia and cardiovascular risk in PD patients.
• Discussion of current therapeutic options, including diet, medications, and dialysis modifications.
• Consideration of high-risk diabetic patients and potential interventions like intraperitoneal insulin.

Main Results:

• PD patients exhibit an unfavorable lipid profile and high C-V mortality rates.
• Conclusive data demonstrating that treating dyslipidemia reduces C-V mortality in PD patients is currently unavailable.
• Current recommendations suggest treating PD patients as high C-V risk, similar to the general population, pending further trials.

Conclusions:

• There is a need to address the 'correctable nihilism' in treating dyslipidemia among PD patients.
• Comprehensive management of all traditional and uremia-related C-V risk factors is crucial for reducing C-V mortality in PD patients.
• Further large-scale trials are required to establish definitive treatment guidelines for dyslipidemia in PD patients to reduce cardiovascular mortality.